IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1704
Positioning
Market Dominance
Manufacturing
Medical Equipment
$160.3B
Gary S. Guthart
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally. invasive approach.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = ISRG ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ISRG INTUITIVE SURGICAL INC | 52 | 66 | 57 | 39 | 67.6x | 67.3x | 14.8% | 12.9% | 66.2% | 28.7% | 28.7% | 24.6% | 0.0% | 14.0x | $160.3B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
INTUITIVE SURGICAL INC (ISRG) receives a "Hold" rating with a composite score of 51.9/100. It ranks #1704 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
High profitability & efficiency — strong quality floor supports entry
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for ISRG.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 66 | 75 | -9DRAG |
| MOMENTUM | 39 | 29 | +10ALPHA |
| VALUATION | 57 | 48 | +9ALPHA |
| INVESTMENT | 29 | 33 | -4NEUTRAL |
| STABILITY | 77 | 81 | -4NEUTRAL |
| SHORT INT | 52 | 58 | -6DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 14.8% (sector -1.9%)
GM 66% vs sector 44%, OM 29% vs sector 3%
Capital turnover N/A, R&D intensity 13.0%
Rev growth 25%, 10yr history
Interest coverage N/A, Net debt/EBITDA -0.8x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate INTUITIVE SURGICAL INC (ISRG) as a Hold with a composite score of 51.9/100 at a current price of $494.70. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
INTUITIVE SURGICAL INC holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 51.9/100 places it at rank #1704 in our full universe.
Narrow
Medium
Exemplary
Fair Value
Gross margins of 66% signal strong pricing power.
Stable competitive position in a defensive sector.
Elevated P/E ratio of 67.6x leaves little room for execution misses.
Vulnerability to macroeconomic shocks and interest rate volatility.
INTUITIVE SURGICAL INC represents a hold based on multi-factor quantitative performance.
Our model assigns INTUITIVE SURGICAL INC a Hold rating, with a composite score of 51.9/100 and 3 out of 5 stars. Ranked #1704 of 7,333 stocks, ISRG presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
ISRG earns a quality score of 66/100, indicating above-average business quality. The company reports a return on equity of 14.8% (sector avg: -1.9%), gross margins of 66.2% (sector avg: 44.1%), net margins of 28.7% (sector avg: 1.0%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
ISRG's value score of 57/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 67.61x, an EV/EBITDA of 67.33x, a P/B ratio of 9.98x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
INTUITIVE SURGICAL INC's investment score of 29/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 24.6% vs. a sector average of 6.7% and a return on assets of 12.9% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
ISRG is currently showing below-average momentum at 39/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 24.6% year-over-year, while a beta of 1.20 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
ISRG shows good financial stability with a score of 77/100. Key stability metrics include a beta of 1.20 and a debt-to-equity ratio of 14.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
The short interest score of 52/100 for ISRG suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include above-average market sensitivity (beta: 1.20), elevated leverage (D/E: 14.00x). With a $160.3B market cap (large-cap), INTUITIVE SURGICAL INC may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
INTUITIVE SURGICAL INC is a large-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1704 of 7,333 overall (77th percentile). Key comparisons include ROE of 14.8% exceeding the -1.9% sector median and operating margins of 28.7% above the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While ISRG currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Stability (77) vs Investment (29) — closing this gap could shift the rating.
EV/EBITDA 488% ABOVE SECTOR MEDIAN
ROE 877% BELOW SECTOR MEDIAN
Gross Margin 50% ABOVE SECTOR MEDIAN (FAVORABLE)
Intuitive Surgical reported strong Q4 2025 results with 19% revenue growth to $2.9 billion and procedure growth of 17% for Da Vinci systems and 44% for Ion systems. The company's recurring revenue (instruments, accessories, and services) represents 75% of total revenue, providing stability. However, the stock trades at a high 70x earnings valuation, and management guided for slower 13-15% procedure growth in 2026 versus 18% in 2025. The article suggests the stock could be a buy for long-term investors despite valuation risks.
Intuitive Surgical ended 2025 strongly with increased da Vinci robot placements and 18% growth in procedures performed. The company's business model is heavily weighted toward recurring revenue (75%) from instruments, accessories, and services. While AI integration presents future growth opportunities, the stock trades at a P/E ratio of 67x, significantly higher than the S&P 500's 28x. The author suggests long-term investors should be patient and wait for a potential deep sell-off before buying.
Abbott Laboratories and Intuitive Surgical are positioned for potential share price gains based on upcoming earnings reports. Abbott, a $211 billion healthcare giant, showed strong CGM product sales growth despite mixed Q3 results, while Intuitive Surgical reported impressive 18% YOY procedure growth and 19% revenue growth, though guidance for 2026 was more modest at 13-15% growth.
Above 50MA
37.18%
Net New Highs
+51081